Interestingly, we previously presented compelling evidence for clinical response to the PI3K inhibitor, gedatolisib, in a metastatic BC patient with a HER2 + tumor harboring PIK3CA mutations, providing a proof-of-concept case [6]. This evidence concerns the gene PIK3CA and neoplasm.